Skip to main content

Viatris Inc(VTRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low14.56
Day High14.90
Open:14.56
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
StockStory
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
NTRA
Motley Fool
QSM Asset Management Loads Up 611,000 Mobileye Shares
Motley Fool
A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound?
Motley Fool
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup
Tipranks
Barclays Keeps Their Buy Rating on Viatris (VTRS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Viatris (VTRS) and Insmed (INSM)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS)
Tipranks
Jefferies Keeps Their Buy Rating on Viatris (VTRS)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pelthos Therapeutics (PTHS) and Viatris (VTRS)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK)
Tipranks
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Hims & Hers Health (HIMS) and Tyra Bioscience (TYRA)
Motley Fool
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
Motley Fool
ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
StockStory
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
CPNG
Tipranks
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
Motley Fool
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Motley Fool
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Motley Fool
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
StockStory
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?
VTRS
StockStory
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4
VTRS
Tipranks
Viatris Earnings Call Highlights Slow Growth, Cash Strength
Tipranks
Analysts Conflicted on These Healthcare Names: Viatris (VTRS) and Green Thumb Industries (OtherGTBIF)
Tipranks
Piper Sandler Remains a Hold on Viatris (VTRS)
Tipranks
Truist Financial Sticks to Their Buy Rating for Viatris (VTRS)
Motley Fool
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
Tipranks
Viatris Launches Major Restructuring After Strong 2025 Results
StockStory
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025
VTRS
StockStory
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow
VTRS
StockStory
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
WDC
StockStory
2 Value Stocks Worth Your Attention and 1 We Brush Off
FRSH
Motley Fool
Better iShares ETF: IJJ's Mid-Cap Focus vs. ISCV's Small-Cap Stocks
Tipranks
Viatris (VTRS) Receives a Hold from J.P. Morgan

Profile

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.